Ms. Guoqiang Liang is a researcher at the Nanjing University of Chinese Medicine whose work centers on traditional Chinese medicine, inflammatory signaling pathways, and the therapeutic potential of herbal compounds in gastrointestinal, renal, and oncological diseases. With a scholarly record comprising 46 publications, 467 citations, and an h-index of 14, she has established a strong research profile that bridges classical medicinal theory with modern biomedical mechanisms. Her recent investigations—such as the study of Panax notoginseng–Bletilla striata for ameliorating reflux esophagitis through the regulation of NLRP3 inflammasomes and p38 MAPK pathways, and the evaluation of Modified Yiyi Fuzi Baijiang Powder on intestinal mucosal permeability in ulcerative colitis—demonstrate her focus on uncovering molecular targets underlying chronic inflammation and tissue injury. Ms. Liang has also contributed to oncology research, particularly through work on compounds like 5-O-Methylvisammioside that inhibit HMGB1-induced angiogenesis in hepatocellular carcinoma via the RAGE/MEK/ERK signaling axis, highlighting her translational interest in natural product–based anticancer strategies. Her extensive collaborative network, reflected by over 130 co-authors, underscores her active engagement in multidisciplinary teams and cross-institution research initiatives. Collectively, Ms. Liang’s research advances the integration of traditional herbal medicine with evidence-based biomedical science, offering mechanistic clarity, therapeutic insights, and potential pathways to novel clinical applications. Her work contributes meaningfully to global efforts aimed at developing safe, mechanism-guided, and culturally informed treatments that address complex inflammatory and neoplastic diseases.
Featured Publications
1. Yang, X., Wu, T., Zhu, H., Ding, H., Chen, X., Xu, Q., Sun, H., & Liang, G. (2026). Panax notoginseng–Bletilla striata ameliorates reflux esophagitis by modulating NLRP3 inflammasomes and p38 MAPK pathway. Cytotechnology, 78(1), 3. https://doi.org/10.1007/s10616-025-00858-9
2. Li, W.-X., Chen, J., He, Z.-C., Zhang, L.-R., Liang, G.-Q., Jiang, X.-X., Wei, Y.-N., & Zhou, Q. (2025). Effect of Modified Yiyi Fuzi Baijiang Powder on intestinal mucosal permeability and expression of AQP3, AQP4 in ulcerative colitis rats. Zhongguo Zhong Yao Za Zhi, 50(14), 3962–3968. https://doi.org/10.19540/j.cnki.cjcmm.20250311.401
3. Hou, W., Zou, T., Yan, Y., Zhuang, Y., Gao, S., Ju, H., Yao, F., Yuan, Q., Zhou, L., Liang, G., Song, X., & Zhang, L. (2025). 5-O-Methylvisammioside inhibits HMGB1-induced angiogenesis of hepatocellular carcinoma through RAGE/MEK/ERK signaling pathway. PLoS One, 20(5), e0322056. https://doi.org/10.1371/journal.pone.0322056
4. Corrigendum to “Shen-yan-yi-hao oral solution ameliorates IgA nephropathy via intestinal IL-17/NF-κB pathway” [J. Ethnopharmacol. 331 (2024) 118335]. (2025). Journal of Ethnopharmacology.
Ms. Guoqiang Liang’s research advances the understanding of traditional Chinese medicine mechanisms, offering novel therapeutic strategies for inflammatory and metabolic diseases. Her work bridges molecular insights with clinical applications, contributing to global health innovation and improving patient outcomes.